[HTML][HTML] A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation

V Zarkhin, L Li, N Kambham, T Sigdel… - American journal of …, 2008 - Elsevier
We report 1-year outcomes of a randomized study of Rituximab versus standard-of-care
immunosuppression (Thymoglobulin and/or pulse steroids) for treatment of biopsy
confirmed, acute transplant rejection with B-cell infiltrates, in 20 consecutive recipients (2–23
years). Graft biopsies, with Banff and CADI scores, CD20 and C4d stains, were performed at
rejection and 1 and 6 months later. Peripheral blood CMV, EBV and BK viral loads, graft
function, DSA, immunoglobulins, serum humanized antichimeric antibody (HACA) and …